rajasekharkakarla
☆    

India,
2019-09-20 06:35

Posting: # 20628
Views: 848
 

 Reference replicated designs [Regulatives / Guidelines]

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
Activity
 Admin contact
20,345 posts in 4,273 threads, 1,402 registered users;
online 5 (0 registered, 5 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 00:15 CET

The internet gave us all the power of speech,
and what did we discover?
That victory goes to he who shouts the loudest,
and that reason does not sell.    Claire North

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5